A study published this month in Genes reveals that even as Alzheimer’s disease presents with similar underlying biomarkers in both men and women, women experience a faster rate of cognitive decline once symptoms emerge. The research, conducted by teams at the University of Minnesota and the University of California, San Francisco, highlights a critical gap in understanding the sex-specific mechanisms driving the disease.
Alzheimer’s disease currently affects approximately 50 million people globally, with women accounting for roughly two-thirds of those diagnosed. Despite this disproportionate impact, research into biomarkers specific to female patients has been historically underfunded, and underdeveloped. The study’s lead authors, Shiwei Huang and Lily Zhong, along with Lilly Zheng and Jian Shi, emphasize the demand for targeted investigation into these differences.
The findings build on growing evidence that blood-based biomarkers are increasingly reliable indicators of Alzheimer’s pathology and predictors of clinical progression. A separate study, published in March 2025 in Nature, demonstrated that levels of p-tau217, amyloid-β42/40 ratio, and neurofilament light chain (NfL) in blood samples correlate with the speed of transition from mild cognitive impairment (MCI) to dementia. The Nature study, which followed over 2,100 dementia-free individuals in Sweden for up to 16 years, found that elevated NfL and p-tau217 were most strongly associated with faster progression.
While the Genes study did not specifically focus on the rate of progression, it underscored the importance of identifying biomarkers that can accurately assess risk and disease stage in women. Researchers note that current diagnostic tools often fail to capture the nuances of how Alzheimer’s manifests in female patients.
The American Academy of Family Physicians (AAFP) recently published an article in May 2025 highlighting the potential of blood biomarkers to improve early detection of cognitive impairment, particularly in primary care settings. The AAFP emphasized that early identification can enable timely interventions and support, but also acknowledged significant health disparities in Alzheimer’s diagnosis and treatment, particularly among Black women who face a greater prevalence of vascular risk factors.
The development of accessible and accurate biomarkers is crucial, as an Alzheimer’s diagnosis currently relies heavily on observing cognitive decline – a point at which substantial brain damage has already occurred. The Alzheimer’s Association has been advocating for increased research into biomarkers to facilitate earlier detection and intervention.
Researchers are currently investigating the role of microRNAs as potential biomarkers for Alzheimer’s disease in women. Further studies are planned to validate these findings and explore the underlying biological mechanisms driving the observed sex-specific differences. Jian Shi, a corresponding author on the Genes study, indicated that the team is preparing for a larger-scale clinical trial to assess the predictive power of these biomarkers in a more diverse population.
